Skip to main content
. 2018 Jul 5;11(4):1044–1052. doi: 10.1016/j.tranon.2018.06.008

Figure 3.

Figure 3

Binding of PSP1 to tumor in radiation dose-dependent therapy. (A) PSP1-flamma675 was injected into the tail vein of mice after receiving radiotherapy 0, 2, 5, 10, and 15 Gy to tumor on right legs. In vivo optical imaging shows the distribution of PSP1 in mouse before and after administration of probe. (B) Quantification of fluorescence signal intensity in mice after administration of PSP1-flamma675 at 6 hours. The results are expressed as the mean ± SD from three independent experiments. Asterisks represent statistical significance compared to control group. Asterisks on brackets represent significance in difference between the two groups. *P < .05 and ***P < .001 by one-way ANOVA. (C) Ex vivo fluorescence images of tumors and (D) their quantification of fluorescence signal. (E) Histological analysis for apoptosis in tumor tissues and (F) quantification of apoptotic positive area. Asterisks represent statistical significance compared to control group. Asterisks on brackets represent significance in difference between the two groups. *P < .05 and ***P < .001 by one-way ANOVA. n.s. indicates not significant.